Replimune Group, Inc. (REPL) on Thursday announced positive results from the primary analysis of the IGNYTE clinical trial involving RP1 and nivolumab for patients with anti-PD1 failed melanoma. Following this news, the stock is up 25%.
The trial's anti-PD1 failed melanoma group included 140 participants, and the primary data revealed a 33.6% overall response rate at the 12-month mark.
The combination of RP1 and nivolumab remains well-tolerated, with predominantly Grade 1-2 constitutional-type side effects being observed.
Furthermore, the company intends to submit a Biologics license application in the latter half of 2024 and is gearing up for a commercial launch next year.
Currently, REPL's stock is trading at $6.99, up 25.68% on Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.